Labeling peptides with technetium-99m using a bifunctional chelator of a N-hydroxysuccinimide ester of mercaptoacetyltriglycine

Journal of Nuclear Medicine

Volumn 39, Issue 1, 1998, Pages 56-64

  Hnatowich, D J ^a   Qu, T ^b   Chang, F ^b   Ley, A C ^b   Ladner, R C ^b   Rusckowski, M ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

MAG3; Peptides; Technetium 99m

Indexed keywords

ANTIPLASMIN; APROTININ; CHELATING AGENT; ELASTASE INHIBITOR; N HYDROXYSUCCINIMIDE S ACETYL MERCAPTOACETYLTRIGLYCINE; RECOMBINANT EPIDERMAL GROWTH FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHELATION; CONJUGATION; HUMAN; HUMAN CELL; ISOTOPE LABELING; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; RADIOCHROMATOGRAPHY; RADIOISOTOPE DISTRIBUTION;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; APROTININ; CATTLE; EPIDERMAL GROWTH FACTOR; HUMANS; ISOTOPE LABELING; MALE; MICE; RADIOPHARMACEUTICALS; SERINE PROTEINASE INHIBITORS; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 0031883114     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bakker WH, Krenning EP, Breeman WA, et al. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity and in vivo application in animals. J Nucl Med 1990;31:1401-1509.
2. Thakur ML. Radiolabelled peptides: now and the future. Nucl Med Commun 1995;16:724-732.
3. Vallabhajosula S, Moyer BR, Lister-James J, et al. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J Nucl Med 1996;37:1016-1022.
4. 99mTc-chelator-peptide conjugates. Bioconj Chem 1996;7:203-208.
5. Fischman AJ, Babich JW, Strauss HW. A ticket to ride: peptide radiopharmaceuticals. J Nucl Med 1993;34:2253-2263.
6. Thakur ML, Eshbach J, Wilder S, John E, McDevitt MR. Technetium-99m-labeled sandostatin: preparation and preliminary evaluation. J Labeled Compound Radiopharm 1993;32:365-367.
7. Knight LC, Radcliffe R, Maurer AH, Rodwell JD, Alvarez VL. Thrombus imaging with technetium-99m synthetic peptides based upon the binding domain of a monoclonal antibody to activated peptides. J Nucl Med 1994;35:282-288.
8. George AJT, Jamar F, Tai M-S, et al. Radiometal labeling of recombinant proteins by a genetically engineered chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. Proc Natl Acad Sci USA 1995;92:8358-8362.
9. Abrams MJ, Juweid M, tenKate CI, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 1990;31:2022-2028.
10. 99mTc using aminocarboxylates as coligands. Bioconj Chem 1996;7:63-71.
11. 99mTc. J Nucl Med 1995;36:2306-2314.
12. Babich JW, Solomon H, Pike MC, et al. Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection. J Nucl Med 1993;34:1964-1974.
13. Fritzberg AR, Berninger RW, Hadley SW, et al. Approaches to radiolabeling of antibodies for diagnosis and therapy of cancer. Pharm Res 1988;5:325-334.
14. Chianelli M, Signore A, Sobnack R, Fritzberg AR, Britton KE, Mather SJ. 99m-Tc-interleukin-1 : a new radiopharmaceutical for the in vivo detection of lymphocytic infiltration. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium and rhenium in chemistry and nuclear medicine. Padova, Italy: S.G. Editoriali; 1995;551-555.
15. Winnard P Jr, Chang F, Rusckowski M, Mardirossian G, Hnatowich DJ. Preparation and use of NHS-MAG3 for technetium-99m labeling of DNA. Nucl Med Biol 1997;24:425-432.
16. Lei K, Rusckowski M, Chang F, Qu T, Mardirossian G, Hnatowich DJ. Technetium-99m antibodies labeled with MAG3 and SHNH-an in vitro and animal in vivo comparison. Nucl Med Biol 1996;23:917-922.
17. Mardirossian G, Lei K, Rusckowski M, Chang F, et al. In vitro hybridization of technetium-99m labeled peptide nucleic acid (PNA). J Nucl Med 1997;38:907-913.
18. Markland W, Ley AC, Lee SW, Ladner RC. Iterative optimization of high-affinity protease inhibitors using display. 1. Plasmin Biochemistry 1996;35:8045-8057.
19. Nosco DL, Wolfangel RG, Bushman MJ, Grummon GD, Marmion ME, Pipes DW. Technetium-99m MAG3: labeling conditions and quality control. J Nucl Med Technol 1993;21:69-74.
20. Grassetti DR, Murray JF Jr. Determination of sulfhydryl groups with 2, 2′-or 4,4′-dithiodipyridine. Arch Biochem Biophys 1967;119:41-49.
21. Rusckowski M, Doherty PW, Virzi F, Hnatowich DJ. A simple in vitro method of screening panels of monoclonal antibodies for tumor binding. J Immunol Methods 1985;76:375-382.
22. 99mTc-labeled to antibodies? Nucl Med Biol 1994;21:1035-1044.
23. Markland W, Ley AC, Lee SW, Ladner RC. Iterative optimization of high-affinity protease inhibitors using phase display.2. Plasma Kallikvein and Thrombin 1996;35: 8058-8067.
24. Mishell BB, Shiigi SM, Henry C, et al. Preparation of mouse cell suspensions. In: Mishell BB, Shiigi SM, eds. Selected methods in cellular immunology. W.H. Freedman and Co.; 1980:16-17.
25. Roberts BL, Markland W, Ley AC, et al. Directed evolution of a protein: selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage. Proc Natl Acad Sci USA 1992;89:2429-2433.
26. a. I. Potent inhibitors selected from libraries by phage display. J Biol Chem 1994;269:22129-22136.
27. 99mTc-mercaptoacetyltriglycine. Nucl Med Biol 1995;22:339-349.
28. Berndt KD, Guntert P, Orbons LP, Wuthrich K. Determination of a high-quality nuclear magnetic resonance solution structure of the bovine pancreatic trypsin inhibitor and comparison with three crystal structures. J Mol Biol 1992;227:757-775.
29. 188Re-labeling of monoclonal antibodies. Cancer 1994;73:769-773.